Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

Table 1 The clinical and treatment characteristics of the patients (n = 173)

Characteristics	n (%)
AJCC 2010 T stage
T1	3 (2)
T2a	74 (43)
T2b	14 (8)
T2c	16 (9)
T3a	49 (28)
T3b	17 (10)
Gleason score (median)	7 (3-9)
Initial PSA (median)	14 ng/dL (2-100 ng/dL)
D’Amico risk group
Intermediate	52 (30)
High	121 (70)
Perineural invasion
Absent	103 (60)
Present	56 (32)
Unknown	14 (8)
Percent positive core biopsy percentage
≤ 50 %	76 (44)
> 50%	59 (34)
Unknown	38 (22)
Radiotherapy dose
736 Gy	145 (84)
76 Gy	16 (16)

T: Tumor.